It works incredibly well for long COVID, Lyme disease, IC, inflammation, etc
It does not establish an authorised indication, effective dose, long-term safety profile or meaningful patient benefit
Since semaglutide further slows gastric emptying as part of its mechanism of action, patients with pre-existing gastroparesis may experience worsening of symptoms including nausea, vomiting, bloating, and abdominal discomfort
Never ignore the symptoms: your safety is the most important thing
However, the longevity of results can vary depending on factors such as age, lifestyle, and the specific treatment used
Animal studies are limited and human data are lacking, making it difficult to assess potential risks to the fetus or nursing infant